Thymosin Alpha-1 (Tα1)
Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.
Thymosin Alpha-1 is the immune-system peptide. Approved in many countries for hepatitis and as adjunct to chemotherapy. Used here for chronic immune issues, post-illness recovery, or as a winter immune-support tool.
Not FDA approved in the U.S. Has orphan drug status for some indications. Approved in 35+ countries (sold as Zadaxin) for hepatitis B/C and chemotherapy adjunct.
Compounding pharmacies may prepare under physician prescription (post Feb 2026 reclassification, pending formal FDA publication).
Interpretation varies — falls outside explicit S2 listing.
Yes outside the U.S. — prescribed by hepatology / oncology providers in countries where Zadaxin is approved.
Who it's for
- →Users with chronic immune issues
- →Post-illness recovery support
- →Cancer / hepatitis-adjunct context under medical care
What to expect
- Week 1
Subtle. Energy / immune-feel often shifts first.
- Week 4
Chronic-illness markers improve in clinical contexts.
- Week 8
Plateau. Cycle off.
Dosing protocol
1.6 mg sub-q, twice weekly. In clinical settings, dosing is condition-specific.
Stacks well with
Side effects
When NOT to use
- ⚠Active immunosuppression therapy (talk to provider)
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • CBC if running long-term
Common mistakes
- • Treating it like an acute immune fix
- • Skipping cycle breaks
- • Underdosing for chronic conditions
Educational only. User-specific dosing is between you and a qualified provider.